-
.
- Akebia Rehabs Inc AKBA introduced topline outcomes from the FO2CUS research examining the efficiency as well as safety and security of vadadustat in hemodialysis individuals transformed from a long-acting erythropoiesis-stimulating representative (ESA) to 3 times regular dental vadadustat application for the upkeep therapy of anemia.
- .
- .
- .
- .
- .
- AKBA shares are up 0.92% at $0.5656 on the last check Monday. .
.(* )The information showed that vadadustat fulfilled the main as well as additional efficiency endpoints as well as was non-inferior to an ESA with a comparable safety and security account to the existing requirement of treatment.
FO2CUS was an open-label, active-controlled, sponsor-blinded research that examined 456 hemodialysis individuals.
In the FO2CUS research, each vadadustat application routine (600mg, 900mg) as well as the consolidated vadadustat-treated team accomplished the main efficiency endpoint of the mean adjustment in Hb in between standard as well as the main analysis duration contrasted to Mircera in grown-up individuals on hemodialysis, showing non-inferiority to Mircera based upon a non-inferiority margin of -0.75 g/dL.
Likewise, each application routine of vadadustat as well as the consolidated vadadustat-treated team accomplished the additional efficiency endpoint of the mean adjustment in Hb in between standard as well as the additional analysis duration.
Akebia anticipates to existing complete research results at a forthcoming clinical meeting or in a peer-reviewed journal this year.
Rate Activity:
© 2023 Benzinga.com. Benzinga does not supply financial investment guidance. All legal rights booked.
